- Home
- ACT vs LEGN Comparison
ACT vs LEGN Comparison
Compare ACT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACT | LEGN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACT | LEGN |
|---|---|---|
| Price | $42.73 | $23.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $44.25 | ★ $61.33 |
| AVG Volume (30 Days) | 226.2K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 3.43 | N/A |
| EPS | ★ 4.52 | N/A |
| Revenue | ★ $1,235,827,000.00 | N/A |
| Revenue This Year | $4.06 | $42.68 |
| Revenue Next Year | $2.33 | $30.52 |
| P/E Ratio | $9.47 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $33.94 | $16.24 |
| 52 Week High | $44.80 | $45.30 |
Technical Indicators
Market Signals| Indicator | ACT | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 62.32 |
| Support Level | $39.43 | $20.70 |
| Resistance Level | $42.80 | $23.68 |
| Average True Range (ATR) | 0.91 | 1.50 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 38.34 | 64.61 |
Price Performance
Historical ComparisonAbout ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.